Policy & Regulation

Janssen’s Esketamine Gets US FDA Panel Endorsement, But With Pricing, Access And Diversion Concerns
Committee overwhelmingly supports approval for treatment-resistant depression but warns that pricing and combination therapy indication could hinder patient access. Esketamine’s risks of sedation and dissociative effects, and its abuse potential, will necessitate a strict risk management strategy.

Bruised Roche Wins Another UK Perjeta Round With Price Cut
In the latest round of what appears to have been a bruising set of price negotiations for Roche, the UK’s cost effectiveness agency NICE has recommended Perjeta in another breast cancer setting.
Policy
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Policy
Commercial, Reimbursement Hurdles Need To Be Addressed By Antimicrobial Resistance Efforts
Melinta describes difficulties launching its new antibiotics at BIO CEO & Investor Conference; companies and other stakeholders urge Congress to enact package of incentives to reinvigorate antibiotic pipeline.
No More Rebates: HHS Proposed Rule Revises Anti-Kickback Safe Harbor
Proposed US rule would establish two new safe harbors against anti-kickback enforcement, one covering price reductions at the point of sale and the other protecting flat service fees paid by manufacturers to pharmacy benefit managers. But rebates to "PBMs to buy formulary position" in Medicare/Medicaid would lose protection.
Generic Advair: Finally Approved, A Long Time Coming
Mylan's generic version of GlaxoSmithKline's blockbuster asthma drug was approved by the US FDA Jan. 30. Scrip's timeline tracks how the commercial value of the drug for GSK has greatly declined from its peak in 2013.
Innovation The Centerpiece In Mixed Japan 2019 Outlook
2019 has already brought one industry-shaking event in Japan with the formal completion of the Takeda-Shire deal. But how will this play out and what else can we expect in this key market over the next year?
US Drug Pricing: What A Difference A Year Makes
Drug makers were optimistic going into 2018 about the political climate and drug pricing environment, but the outlook is more tenuous heading into 2019. Now is the time when industry raises prices on mature, marketed drugs and it's unclear how those hikes may be tempered or what the backlash might be.
Pharma: Be Prepared For Tougher Price Negotiations For IO Combos And Expansions In Europe
Payers are increasingly likely to implement new strategies to manage price negotiations for immuno-oncology combinations, as competition heats up among the drug class. Mechanisms allowing for the negotiation of different prices for combination therapies do not exist at present, but payers insist that new tools must emerge.
Regulation
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Regulation
Mortality Signal For Pfizer's Xeljanz In Rheumatoid Arthritis Puts A Damper On JAK Class
Analyst speculates that risk of pulmonary embolism for a higher unapproved dose of Xeljanz in arthritis could trigger a label change for the same regimen in the drug's ulcerative colitis indication.
AZ And Ipsen Outline Brexit Contingency Plans
With the UK no nearer to deciding how hard or soft its exit from the EU will be on March 29, AstraZeneca and Ipsen have given updates on their efforts to cope with the chaos that could ensue on the medicines supply front.
Infographic: The Netherlands, A Small Country With Big Ideas
As the EMA lowers the flags of the 28 EU nations that have flown outside its London offices for 24 years, and prepares to moves its HQ to the Netherlands, Scrip takes a look at Europe’s new pharma regulatory hub.
In A Record Year For US FDA Approvals, Pfizer Came Out On Top
Anticancers, Orphans & The First CAR-Ts: New EU Drug Approvals In 2018
New approvals in the EU were again dominated by oncology drugs in 2018, although medicines for infectious diseases were a close second. The number of orphan drugs more than doubled over the previous year, to 17. There were also some star arrivals in multiple sclerosis, genetic disorders, metabolism and migraine.
Luxturna Approved In EU: Novartis Outlines Lessons For Gene Therapy Strategies
The European Commission has officially approved Luxturna, Novartis/Spark Therapeutics’ transformative gene therapy. The Swiss firm tells Scrip how the lessons it expects to learn from launching its first gene therapy will inform its future strategy in this new field.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.